Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis

29 Oct 2012

Abstract excerpt

The nutrient-sensing mTOR (mammalian Target of Rapamycin) pathway regulates cellular metabolism, growth functions, and proliferation and is involved in age-related diseases including cancer, type 2 diabetes, neurodegeneration and cardiovascular disease. The inhibition of mTOR by rapamycin, or calorie restriction, has been shown to extend lifespan and delays tumorigenesis in several experimental models suggesting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23117593
DOI: 10.18632/aging.100496

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesisPMID 23117593Read ↗

Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− miceSemantic proximity Read ↗

Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.Semantic proximity Read ↗

Rapamycin extends maximal lifespan in cancer-prone mice.Semantic proximity Read ↗

Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR InhibitorSemantic proximity Read ↗

The bioavailability of compounded and generic rapamycin in normative aging individuals: A retrospective study and review with clinical implicationsSemantic proximity Read ↗

Rapamycin-PLGA microspheres induce autophagy and prevent senescence in chondrocytes and exhibit long <i>in vivo</i> residenceSemantic proximity Read ↗

A novel rapamycin analog is highly selective for mTORC1 in vivoSemantic proximity Read ↗

Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma.Semantic proximity Read ↗

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.Semantic proximity Read ↗

Evaluating the effect of rapamycin treatment in Alzheimer's Disease and aging using<i>in vivo</i>imaging: the ERAP phase IIa clinical study protocolSemantic proximity Read ↗

Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With MacropinocytosisSemantic proximity Read ↗

Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy <i>in Vivo</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.